Loading...

Mithra Pharmaceuticals

DB:1TM
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1TM
DB
€925M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
1TM Share Price and Events
7 Day Returns
-1.4%
DB:1TM
-3.3%
DE Pharmaceuticals
-2.3%
DE Market
1 Year Returns
-20.9%
DB:1TM
-30.8%
DE Pharmaceuticals
-11.5%
DE Market
1TM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mithra Pharmaceuticals (1TM) -1.4% -5.4% -4.8% -20.9% 161.9% -
DE Pharmaceuticals -3.3% -8.4% -12.1% -30.8% -21.4% 7.5%
DE Market -2.3% -4.9% 0.8% -11.5% 5.7% 6.6%
1 Year Return vs Industry and Market
  • 1TM outperformed the Pharmaceuticals industry which returned -30.8% over the past year.
  • 1TM underperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
1TM
Industry
5yr Volatility vs Market
Related Companies

1TM Value

 Is Mithra Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mithra Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €24.76.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mithra Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mithra Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1TM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-0.75
ENXTBR:MITRA Share Price ** ENXTBR (2019-05-24) in EUR €24.54
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 27.96x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 20.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mithra Pharmaceuticals.

DB:1TM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:MITRA Share Price ÷ EPS (both in EUR)

= 24.54 ÷ -0.75

-32.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mithra Pharmaceuticals is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Mithra Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mithra Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:1TM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -32.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
81%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.85x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mithra Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mithra Pharmaceuticals's assets?
Raw Data
DB:1TM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.01
ENXTBR:MITRA Share Price * ENXTBR (2019-05-24) in EUR €24.54
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.27x
Germany Market PB Ratio Median Figure of 577 Publicly-Listed Companies 1.77x
DB:1TM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:MITRA Share Price ÷ Book Value per Share (both in EUR)

= 24.54 ÷ 4.01

6.12x

* Primary Listing of Mithra Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mithra Pharmaceuticals is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Mithra Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Mithra Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

1TM Future Performance

 How is Mithra Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
81%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mithra Pharmaceuticals expected to grow at an attractive rate?
  • Mithra Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mithra Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Mithra Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1TM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1TM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 81%
DB:1TM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 40.7%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 17.2%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 3.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1TM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1TM Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 127 19 26 1
2019-12-31 142 25 69 2
DB:1TM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 58 4 -28
2018-09-30 46 -12 -41
2018-06-30 47 -32 -50
2018-03-31 47 -33 -43
2017-12-31 32 -31 -38
2017-09-30 26 -32 -37
2017-06-30 20 -32 -36
2017-03-31 21 -28 -36
2016-12-31 22 -23 -35
2016-09-30 21 -23 -29
2016-06-30 20 -22 -23
2016-03-31 20 -20 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mithra Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Mithra Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1TM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Mithra Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1TM Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31 2.21 2.21 2.21 1.00
DB:1TM Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -0.75
2018-09-30 -1.08
2018-06-30 -1.46
2018-03-31 -1.27
2017-12-31 -1.17
2017-09-30 -1.16
2017-06-30 -1.15
2017-03-31 -1.14
2016-12-31 -1.13
2016-09-30 -0.86
2016-06-30 -0.63
2016-03-31 -0.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mithra Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mithra Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mithra Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

1TM Past Performance

  How has Mithra Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mithra Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mithra Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mithra Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mithra Pharmaceuticals's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Mithra Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mithra Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1TM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 57.88 -27.61 10.96 35.71
2018-09-30 45.58 -40.52 10.34 38.90
2018-06-30 47.49 -50.08 12.68 42.08
2018-03-31 46.87 -42.54 13.04 45.13
2017-12-31 32.04 -38.36 10.43 48.19
2017-09-30 25.81 -37.16 11.81 45.55
2017-06-30 19.58 -35.95 13.19 42.91
2017-03-31 21.03 -35.52 14.49 38.60
2016-12-31 22.47 -35.09 15.79 34.30
2016-09-30 21.43 -29.12 17.31 28.93
2016-06-30 20.38 -23.15 18.84 23.56
2016-03-31 20.41 -16.49 17.09 16.52
2015-12-31 20.44 -9.82 15.34 9.49
2015-09-30 19.39 -8.81 12.81 6.82
2015-06-30 18.34 -7.79 10.28 4.15
2015-03-31 18.69 -5.37 10.01 3.38
2014-12-31 19.04 -2.96 9.75 2.61
2013-12-31 17.68 -1.53 7.90 1.38
2012-12-31 14.75 -0.63 6.59 0.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mithra Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mithra Pharmaceuticals has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mithra Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mithra Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mithra Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

1TM Health

 How is Mithra Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mithra Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mithra Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mithra Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mithra Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mithra Pharmaceuticals Company Filings, last reported 4 months ago.

DB:1TM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 150.89 186.50 118.95
2018-09-30 150.89 186.50 118.95
2018-06-30 127.84 147.26 85.76
2018-03-31 127.84 147.26 85.76
2017-12-31 86.88 119.49 36.19
2017-09-30 86.88 119.49 36.19
2017-06-30 99.98 85.97 44.75
2017-03-31 99.98 85.97 44.75
2016-12-31 93.02 55.20 45.75
2016-09-30 93.02 55.20 45.75
2016-06-30 108.15 46.76 65.90
2016-03-31 108.15 46.76 65.90
2015-12-31 127.39 55.55 96.79
2015-09-30 127.39 55.55 96.79
2015-06-30 54.17 30.64 26.51
2015-03-31 54.17 30.64 26.51
2014-12-31 5.52 5.22 1.68
2013-12-31 2.49 4.69 1.56
2012-12-31 2.01 4.92 0.70
  • Mithra Pharmaceuticals's level of debt (123.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (187.7% vs 123.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mithra Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Mithra Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -5.5% each year.
X
Financial health checks
We assess Mithra Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mithra Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

1TM Dividends

 What is Mithra Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mithra Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Mithra Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mithra Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mithra Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1TM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3.3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1TM Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31 0.00 1.00
DB:1TM Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2015-09-04 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mithra Pharmaceuticals has not reported any payouts.
  • Unable to verify if Mithra Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mithra Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mithra Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mithra Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Mithra Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mithra Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mithra Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

1TM Management

 What is the CEO of Mithra Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Francois Fornieri
CEO Bio

Mr. Francois Fornieri served as a Director of VOO until March 29, 2017. Mr. Fornieri serves as the Chief Executive Officer and Chief Business Development Officer at Mithra Pharmaceuticals SA. Mr. Fornieri serves as Managing director of Eole Racing Events SPRL; Le Fiacre SA; Novalon SA; Le Bocholtz SA; Fund SA; Mithra Pharmaceuticals CDMO SA; Mithra R&D SA; Vitamines Events SA; Belgian Motor Group SA and Yima Luxembourg SàRL. He is founder of Mithra Pharmaceuticals. He co-founded Uteron Pharma SA and served as its Co-Chief Executive Officer. Mr. Fornieri has over 25 years of pharmaceutical experience with a strong focus on female healthcare. He served as Managing Director of Ardentia Invest SA; Mithra IBD SA ; Mithra RDP SA; Uteron Pharma SA; Odyssea Pharma SA; Uteron Pharma Technology SA and Femalon SA. He was employed at Bayer-Schering. He serves as an Executive Director of Mithra Pharmaceuticals SA. He serves as Director of Yima SPRL; Symbiose Biomaterials SA; Semeb SA; Les amis de M SCRL; Meusinvest SA; Cide-Socran ASBL; Le Fiacre SA; Imperia Automobiles SA; Novalon SA; Union Wallonne des Entreprises ASBL; Estetra SA; Mithra Pharmaceuticals GmbH; Biogenosis SA (as permanent representative of Yima SPRL); Le Bocholtz SA; Fund SA; Mithra Pharmaceuticals CDMO SA; Mithra R&D SA o Managing Director and Director of Themis Holding SA; BIOWIN; Vitamines Events SA; Belgian Motor Group SA; Protection Unit SA and GUSTA SPRL. He served as a Member of the Board of Directors at Uteron Pharma SA. He served as a Director at Geninvest SCRL; Ardentia Invest SA; Mithra IBD SA; Mithra RDP SA; Uteron Pharma SA; Odyssea Pharma SA; Uteron Pharma Technology SA and Femalon SA. He has been elected the French speaking 2011 Manager of the year by the Belgian business magazine Trends/Tendances. He obtained a degree in Chemistry.

CEO Compensation
  • Insufficient data for Francois to compare compensation growth.
  • Insufficient data for Francois to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the Mithra Pharmaceuticals management team in years:

1.7
Average Tenure
  • The average tenure for the Mithra Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Francois Fornieri

TITLE
CEO, Chief Business Development Officer & Executive Director

Christophe Maréchal

TITLE
Chief Financial Officer
TENURE
2.3 yrs

Valérie Gordenne

TITLE
Chief Scientific Officer

Patrick Kellens

TITLE
Chief Information Officer

Alexandra Deschner

TITLE
Investor Relations Officer
TENURE
0.3 yrs

Michaël Dillen

TITLE
Chief Legal Officer
TENURE
2.3 yrs

Jan Van Der Auwera

TITLE
Chief Marketing Officer

Jean-Michel Foidart

TITLE
President of the Scientific Advisory Board & Executive Director
COMPENSATION
€7K

Geoffroy Dieu

TITLE
Chief Production Officer
TENURE
1.2 yrs

Benjamin Brands

TITLE
Chief Supply Chain Officer
Board of Directors Tenure

Average tenure and age of the Mithra Pharmaceuticals board of directors in years:

2.7
Average Tenure
50
Average Age
  • The average tenure for the Mithra Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marc Armand Alice André Coucke

TITLE
Non-Executive Chairman
COMPENSATION
€45K
AGE
53
TENURE
2.7 yrs

Francois Fornieri

TITLE
CEO, Chief Business Development Officer & Executive Director

Jean-Michel Foidart

TITLE
President of the Scientific Advisory Board & Executive Director
COMPENSATION
€7K

Jacques Platieau

TITLE
Independent Director
COMPENSATION
€25K

Koen Hoffman

TITLE
Independent Director
COMPENSATION
€25K
AGE
50
TENURE
2.7 yrs

Marc Beyens

TITLE
Non Executive Director
COMPENSATION
€20K

Guy Debruyne

TITLE
Non Executive Director
COMPENSATION
€20K

Gaëtan Servais

TITLE
Non-Executive Director
COMPENSATION
€25K

Philippe Suinen

TITLE
Independent Director
COMPENSATION
€28K

Freya Loncin

TITLE
Non-Executive Director
COMPENSATION
€20K
AGE
44
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mithra Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mithra Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

1TM News

Simply Wall St News

1TM Company Info

Description

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which is in phase III clinical trial for oral contraceptive; Donesta, which is in phase II clinical trial for vasomotor symptoms in postmenopausal women; and PeriNesta, an oral treatment for perimenopause. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. It provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals S.A. was founded in 1999 and is headquartered in Liège, Belgium.

Details
Name: Mithra Pharmaceuticals S.A.
1TM
Exchange: DB
Founded: 1999
€924,887,937
37,688,995
Website: http://www.mithra.com
Address: Mithra Pharmaceuticals S.A.
Rue Saint-Georges 5,
Liège,
Liège, 4000,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR MITRA Common Shares Euronext Brussels BE EUR 30. Jun 2015
DB 1TM Common Shares Deutsche Boerse AG DE EUR 30. Jun 2015
LSE 0R91 Common Shares London Stock Exchange GB EUR 30. Jun 2015
Number of employees
Current staff
Staff numbers
129
Mithra Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 22:08
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/04/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.